Alvin H. Schmaier, MD

home / authors / alvin-h-schmaier-md

Articles

Dr. Schmaier on Managing Cancer-Associated Thrombosis

Dr. Schmaier on Managing Cancer-Associated Thrombosis

Alvin H. Schmaier, MD
April 17th 2020

Alvin H. Schmaier, MD, professor in the Department of Medicine and the Department of Pathology at Case Western Reserve University School of Medicine, discusses the management of patients with cancer-associated thrombosis.

Read More

Dr. Schmaier on the Secondary Management of Thrombosis in Hematologic Malignancies

Dr. Schmaier on the Secondary Management of Thrombosis in Hematologic Malignancies

Alvin H. Schmaier, MD
April 14th 2020

Alvin H. Schmaier, MD, discusses the secondary management of thrombosis in patients with hematologic malignancies.

Read More

Dr. Schmaier on Managing Thrombosis in Hematologic Malignancies

Dr. Schmaier on Managing Thrombosis in Hematologic Malignancies

Alvin H. Schmaier, MD
March 28th 2020

Alvin H. Schmaier, MD, discusses managing thrombosis in patients with hematologic malignancies.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data